Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Malignant Lymphoma

  Free Subscription


20.05.2019

1 Br J Cancer
2 Br J Haematol
1 Haematologica
1 Int J Cancer
1 Lancet Oncol
2 Leuk Lymphoma
2 Leukemia
1 Oncology (Williston Park)
1 Proc Natl Acad Sci U S A


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Br J Cancer

  1. MAES A, Maes K, De Raeve H, De Smedt E, et al
    The anaphase-promoting complex/cyclosome: a new promising target in diffuse large B-cell lymphoma and mantle cell lymphoma.
    Br J Cancer. 2019 May 15. pii: 10.1038/s41416-019-0471.
    PubMed     Text format     Abstract available


    Br J Haematol

  2. TOYODA K, Tsukasaki K, Machida R, Kadota T, et al
    Possibility of a risk-adapted treatment strategy for untreated aggressive adult T-cell leukaemia-lymphoma (ATL) based on the ATL prognostic index: a supplementary analysis of the JCOG9801.
    Br J Haematol. 2019 May 16. doi: 10.1111/bjh.15950.
    PubMed     Text format     Abstract available

  3. NIJDAM A, Dekker N, Aleman BMP, van 't Veer MB, et al
    Setting up a national infrastructure for survivorship care after treatment for Hodgkin lymphoma.
    Br J Haematol. 2019 May 15. doi: 10.1111/bjh.15936.
    PubMed     Text format    


    Haematologica

  4. YUAN CT, Huang TC, Chuang CC, Chuang YK, et al
    Clonal sequence tracking reveals TET2-mutated extranodal NK/T-cell lymphoma disseminated independent of EB virus.
    Haematologica. 2019 May 16. pii: haematol.2018.215327.
    PubMed     Text format    


    Int J Cancer

  5. PARODI S, Seniori Costantini A, Crosignani P, Fontana A, et al
    Childhood infectious diseases and risk of non-Hodgkin's lymphoma according to the WHO classification: a reanalysis of the Italian multicentre case-control study.
    Int J Cancer. 2019 May 11. doi: 10.1002/ijc.32393.
    PubMed     Text format     Abstract available


    Lancet Oncol

  6. GOURD E
    New treatment for relapsed or refractory Hodgkin's lymphoma.
    Lancet Oncol. 2019 May 10. pii: S1470-2045(19)30289.
    PubMed     Text format    


    Leuk Lymphoma

  7. PING N, Qu C, Bai L, Kang L, et al
    Successful chimeric antigen receptor T cell therapy in a case of primary testicular diffuse large-B-cell lymphoma with central nervous system progression.
    Leuk Lymphoma. 2019 May 14:1-3. doi: 10.1080/10428194.2019.1605507.
    PubMed     Text format    

  8. HORGAN C, Elmoamly S, McIlroy G, Davies D, et al
    Reduced intensity alemtuzumab-containing allogeneic stem cell transplantation for relapsed/refractory low grade lymphoma: reflections on a single center experience.
    Leuk Lymphoma. 2019 May 13:1-3. doi: 10.1080/10428194.2019.1607323.
    PubMed     Text format    


    Leukemia

  9. WATATANI Y, Sato Y, Miyoshi H, Sakamoto K, et al
    Molecular heterogeneity in peripheral T-cell lymphoma, not otherwise specified revealed by comprehensive genetic profiling.
    Leukemia. 2019 May 15. pii: 10.1038/s41375-019-0473.
    PubMed     Text format     Abstract available

  10. LUPINO L, Perry T, Margielewska S, Hollows R, et al
    Sphingosine-1-phosphate signalling drives an angiogenic transcriptional programme in diffuse large B cell lymphoma.
    Leukemia. 2019 May 16. pii: 10.1038/s41375-019-0478.
    PubMed     Text format     Abstract available


    Oncology (Williston Park)

  11. KALLAM A, Vose JM
    Hope After Salvage Therapy Fails: Novel Agents for Relapsed/Refractory Hodgkin Lymphoma.
    Oncology (Williston Park). 2019;33.
    PubMed     Text format     Abstract available


    Proc Natl Acad Sci U S A

  12. SANG P, Zhang M, Shi Y, Li C, et al
    Inhibition of beta-catenin/B cell lymphoma 9 protein-protein interaction using alpha-helix-mimicking sulfono-gamma-AApeptide inhibitors.
    Proc Natl Acad Sci U S A. 2019 May 14. pii: 1819663116.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: